ArticleVirology journal2025
Adverse events following measles, mumps, rubella and varicella virus vaccine live (PROQUAD
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Surveillance and analysis of adverse events following immunization (AEFI) with measles, mumps, and rubella (MMR) vaccine in Zhejiang Province, China, 2020-2025.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPROQUAD
methodsWe performed a disproportionality analysis of PROQUAD-related adverse events (AEs) reported to the Vaccine Adverse Event Reporting System (VAERS) between 2015 and 2025. Multiple statistical algorithms were applied to detect safety signals, supplemented by stratified analyses across age, sex, severity, and fatal outcomes.
resultsAmong 17,234 reports, the most frequently reported AEs included injection site erythema, swelling, and fever, consistent with established reactogenicity. Several statistically significant signals not listed in the current FDA label were identified, such as febrile convulsion, vaccination failure, cyanosis, and influenza-like illness. These unlabeled events exhibited distinct patterns across age and sex subgroups, with serious and fatal outcomes occurring more frequently in children under three years of age and in medically vulnerable individuals. Most AEs occurred within three days of vaccination, although serious events showed delayed onset profiles.
conclusionThis real-world pharmacovigilance analysis confirms the expected safety profile of PROQUAD while revealing additional adverse event signals that merit further clinical investigation and potential regulatory attention. Continued monitoring is essential to inform vaccine safety practices, particularly in pediatric populations with heightened susceptibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.